Paratek's antibiotic succeeds in second late-stage study

(Reuters) - Paratek Pharmaceuticals Inc said on Monday its experimental lead antibiotic succeeded in a second late-stage study, bringing it one step closer to applying for marketing approvals in the United States and Europe.